Aquestive Therapeutics, Inc. (AQST): Corporate Presentation November 2026

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Regulation FD Disclosure. Corporate Presentation November 2026 Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking statements” within the meaning of the Private S

Original reporting
Published Nov 5, 2026, 9:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AQST
Neutral
medium confidence
Mentioned
$AQST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

No new quantitative guidance or milestones are disclosed, limiting immediate trading relevance.

02

Market read

The filing is a routine regulatory disclosure with minimal immediate market impact.

03

What to watch

The filing hints at upcoming FDA interactions that could become material if timelines shift, but no dates are confirmed.

Relevance 4/10Novelty 4/10Timing: upon filing

Background

The SEC Form 8‑K contains a corporate presentation with forward‑looking statements about product candidates, regulatory timelines, and commercial plans.

Company-level read

Ticker impact

$AQSTNeutralMedium confidence
Context

AQST filed a Regulation FD disclosure presenting forward-looking statements about its product pipeline and anticipated FDA review timelines.

Expected impact

likely neutral as the market absorbs the forward-looking commentary without concrete numbers

Evidence & confidence

Without specific financial metrics or milestones, traders have little actionable information; the disclosure mainly restates expectations.

Market effects

Limited impact on the biotech/pharma sector as the company only reiterates existing development plans.

No discernible regional effect.

Minimal global relevance.

Counterpoint

Investors may view the lack of concrete milestones as a sign of delayed progress, potentially weighing on the stock.

Key entities

  • Aquestive Therapeutics, Inc.

    Biopharma company developing epinephrine delivery products.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.